RT Journal Article
T1 Marine guanidine alkaloids crambescidins inhibit tumor growth and activate intrinsic apoptotic signaling inducing tumor regression in a colorectal carcinoma zebrafish xenograft model
A1 Roel Sánchez, María
A1 Rubiolo Gaytán, Juan Andrés
A1 Guerra Varela, Jorge
A1 Silva, Siguara B. L.
A1 Thomas, Olivier P.
A1 Cabezas Sáinz, Pablo
A1 Sánchez Piñón, Laura
A1 López López, Rafael
A1 Botana López, Luis Miguel
AB The marine environment constitutes an extraordinary resource for the discovery of new therapeutic agents. In the present manuscript we studied the effect of 3 different sponge derived guanidine alkaloids, crambescidine-816, -830, and -800. We show that these compounds strongly inhibit tumor cell proliferation by down-regulating cyclin-dependent kinases 2/6 and cyclins D/A expression while up-regulating the cell cyclin-dependent kinase inhibitors -2A, -2D and -1A. We also show that these guanidine compounds disrupt tumor cell adhesion and cytoskeletal integrity promoting the activation of the intrinsic apoptotic signaling, resulting in loss of mitochondrial membrane potential and concomitant caspase-3 cleavage and activation. The crambescidin 816 anti-tumor effect was fnally assayed in a zebrafish xenotransplantation model confirming its potent antitumor activity against colorectal carcinoma in vivo.Considering these results crambescidins could represent promising natural anticancer agents and therapeutic tools
PB Impact Journals
SN 1949-2553
YR 2016
FD 2016
LK http://hdl.handle.net/10347/26114
UL http://hdl.handle.net/10347/26114
LA eng
NO Roel M., Rubiolo J. A., Guerra-Varela J., Silva S. B. L., Thomas O. P., Cabezas-Sainz P., Sánchez L., López R., Botana L. M. Marine guanidine alkaloids crambescidins inhibit tumor growth and activate intrinsic apoptotic signaling inducing tumor regression in a colorectal carcinoma zebrafish xenograft model. Oncotarget. 2016; 7: 83071-83087. Retrieved from https://www.oncotarget.com/article/13068/text/
NO The research leading to these results has received funding from the following FEDER cofunded-grants. From CDTI and Technological Funds, supported by Ministerio de Economía y Competitividad, AGL2012-40185-CO2-01, AGL2014-58210-R, and Consellería de Cultura, Educación e Ordenación Universitaria, GRC2013-016. From CDTI under ISIP Programme, Spain, IDI-20130304 APTAFOOD. From the European Union’s Seventh Framework Programme managed by REA – Research Executive Agency (FP7/2007-2013) under grant agreement 312184 PHARMASEA. M.R.S. is an I2C predoctoral fellow. From CAPES Foundation, Brazil (scholarship process: BEX 10184-13-9)
DS Minerva
RD 22 abr 2026